Table 1. Characteristics of patients according to overprescription of a PPI (n = 280).
| Characteristics | Overprescription of PPI | p-value* | |
|---|---|---|---|
| No(n = 73) | Yes(n = 207) | ||
| Age (years), mean ± SD | 85.4 ± 5.4 | 86.7 ± 7.9 | 0.173 |
| Female sex, n (%) | 47 (64.4) | 147 (71) | 0.304 |
| Living in nursing home, n (%) | 12 (16.4) | 48 (23.2) | 0.250 |
| BMI, mean ± SD | 25.8 ± 4.7 | 25.4 ±5.1 | 0.706 |
| ADL/6, mean ± SD | 4.12 ± 1.9 | 3.9 ±1.9 | 0.385 |
| Number of concomitant medications, mean ±SD | 8.1 ± 2.7 | 9.0 ± 2.8 | 0.018 |
| Full dose of PPI, n (%) | 35 (47.9) | 74 (35.7) | 0.071 |
| Microcytic anemia, n (%) | 2 (2.7) | 17 (8.2) | 0.174 |
| Hiatal hernias, n (%) | 10 (13.7) | 33 (15.9) | 0.709 |
| Type of concomitant medications | |||
| Antiaggregants, n (%) | 33 (45.2) | 99 (47.8) | 0.685 |
| Cortisteroids’, n (%) | 2 (2.7) | 34 (16.5) | 0.002 |
| Anticoagulants, n (%) | 19 (26) | 55 (26.6) | 0.911 |
| Associated multimorbidities | |||
| CIRS, mean ± SD | 9.6 ± 3.4 | 10.8 ± 3.6 | 0.031 |
| Cardiac diseases, n (%) | 58 (79.5) | 197 (95.2) | <0.001 |
| Metabolic diseases, n (%) | 19 (26) | 81 (39.1) | 0.048 |
| Esogastric diseases, n (%) | 42 (57.5) | 78 (37.7) | 0.004 |
| Vascular diseases, n (%) | 30 (41.1) | 117 (56.5) | 0.029 |
*based on independent samples Chi-square or t-test as appropriate, with P significant at ≤0.05; significant P-values (i.e. ≤0.05) are indicated in bold